Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1964 2
1970 2
1978 1
1979 1
1985 1
1986 2
1990 1
1991 2
1993 4
1994 5
1996 4
1997 2
1998 1
1999 1
2000 1
2001 3
2002 2
2003 2
2004 2
2005 5
2006 3
2007 7
2008 7
2009 3
2010 7
2011 5
2012 12
2013 19
2014 19
2015 28
2016 22
2017 21
2018 30
2019 29
2020 42
2021 40
2022 39
2023 43
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

374 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: de melo ac. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: de melo ac. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Diagnostic imaging in bronchial atresia.
de Melo ASA. de Melo ASA. Radiol Bras. 2021 Mar-Apr;54(2):V. doi: 10.1590/0100-3984.2021.54.2e1. Radiol Bras. 2021. PMID: 33854270 Free PMC article. No abstract available.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM. Kristeleit R, et al. Among authors: de melo ac. Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14. Lancet Oncol. 2022. PMID: 35298906 Clinical Trial.
Molecular landscape of Hereditary Melanoma.
Ribeiro Moura Brasil Arnaut J, Dos Santos Guimarães I, Evangelista Dos Santos AC, de Moraes Lino da Silva F, Machado JR, de Melo AC. Ribeiro Moura Brasil Arnaut J, et al. Among authors: de melo ac. Crit Rev Oncol Hematol. 2021 Aug;164:103425. doi: 10.1016/j.critrevonc.2021.103425. Epub 2021 Jul 7. Crit Rev Oncol Hematol. 2021. PMID: 34245855 Review.
Implementation of a pharmacogenomic program in a Brazilian public institution.
Suarez-Kurtz G, Kovaleski G, Elias AB, Motta V, Wolch K, Emerenciano M, Mansur MB, Palladino AM, Accioly MT, Ferreira M, Gonçalves AA, de Melo AC. Suarez-Kurtz G, et al. Among authors: de melo ac. Pharmacogenomics. 2020 Jun;21(8):549-557. doi: 10.2217/pgs-2020-0016. Epub 2020 May 7. Pharmacogenomics. 2020. PMID: 32378980 Review.
A Review of mTOR Pathway Inhibitors in Gynecologic Cancer.
de Melo AC, Paulino E, Garces ÁH. de Melo AC, et al. Oxid Med Cell Longev. 2017;2017:4809751. doi: 10.1155/2017/4809751. Epub 2017 Feb 13. Oxid Med Cell Longev. 2017. PMID: 28286604 Free PMC article. Review.
Phages as friends and enemies in food processing.
de Melo AG, Levesque S, Moineau S. de Melo AG, et al. Curr Opin Biotechnol. 2018 Feb;49:185-190. doi: 10.1016/j.copbio.2017.09.004. Epub 2017 Oct 5. Curr Opin Biotechnol. 2018. PMID: 28987913 Review.
Horticultural Crops under Stresses.
de Melo AS, Gheyi HR. de Melo AS, et al. Plants (Basel). 2023 Sep 26;12(19):3400. doi: 10.3390/plants12193400. Plants (Basel). 2023. PMID: 37836140 Free PMC article.
374 results